Eli Lilly beats profit forecast amid soaring weight-loss drug demand

© Reuters

Eli Lilly (NYSE:) has reported fourth-quarter adjusted earnings per share of $2.49, topping Bloomberg consensus estimates, thanks in part to soaring demand for its diabetes treatment.

Shares in the U.S. drugmaker moved higher in premarket trading on Tuesday.


This website uses cookies. By continuing to use this site, you accept our use of cookies.